1. Talapko J, Škrlec I, Alebić T, Jukić M, Včev A. Malaria: The Past and the Present. Microorganisms. 2019;7(6):179. Published 2019 Jun 21. doi:10.3390/microorganisms7060179
2. World Health Organization. WHO guidelines for Malaria. WHO. 2022. https://apps.who.int/iris/rest/bitstreams/1411121/retrieve
3. Dicko A, Brown JM, Diawara H, Baber I, Mahamar A, Soumare HM, Sanogo K, Koita F, Keita S, Traore SF, Chen I. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. The Lancet Infectious Diseases. 2016 Jun 1;16(6):674-84.
4. Milner DA Jr. Malaria Pathogenesis. Cold Spring Harb Perspect Med. 2018;8(1):a025569. Published 2018 Jan 2. doi:10.1101/cshperspect.a025569
5. Herchline T, Simon R. Malaria. Medscape. 2020. https://emedicine.medscape.com/article/221134-overview
6. Hill SR, Thakur RK, Sharma GK. Antimalarial Medications. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan
7. Tine RC, Sylla K, Faye BT, Poirot E, Fall FB, Sow D, Wang D, Ndiaye M, Ndiaye JL, Faye B, Greenwood B. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical infectious diseases. 2017 Aug 15;65(4):535-43.
8. Mwaiswelo RO, Ngasala B, Msolo D, Kweka E, Mmbando BP, Mårtensson A. A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania. Malaria Journal. 2022 Dec;21(1):1-5.
9. Uthman OA, Graves PM, Saunders R, Gelband H, Richardson M, Garner P. Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies. Malaria journal. 2017 Dec;16(1):1-4.